Metformin Hydrochloride Tablets Recalled for NDMA Contamination
Viona Pharmaceuticals is recalling Metformin Hydrochloride Extended-Release Tablets 750 mg due to detection of N-Nitrosodimethylamine (NDMA) levels exceeding acceptable daily intake limits.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving detection of a genotoxic impurity (NDMA) without reported illnesses. The hazard presents a potential health risk based on established safety standards, meeting the High severity criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Viona Pharmaceuticals Inc. is recalling Metformin Hydrochloride Extended-Release Tablets, USP 750 mg (NDC 72578-036-01) distributed nationwide in the United States. The recall was initiated due to CGMP deviations and detection of N-Nitrosodimethylamine (NDMA) at levels that exceed the FDA's Acceptable Daily Intake Limit.
The affected product consists of 21,240 bottles from Lot M915601 and Lot M915602, manufactured by Cadila Healthcare Ltd. in Ahmedabad, India, and distributed by Viona Pharmaceuticals Inc. in Cranford, New Jersey.
Consumers taking this medication should contact their healthcare provider or pharmacist for guidance. Patients should not stop taking metformin without consulting their healthcare provider, as abrupt discontinuation may affect their diabetes management. Healthcare providers and pharmacists should identify and quarantine affected inventory and notify their wholesalers of the recall.
The recalled product
- Product
- METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE)
- Brand
- METFORMIN HYDROCHLORIDE
- Manufacturer
- VIONA PHARMACEUTICALS INC
- Category
- Drug — Prescription / Generic
- Affected units
- 21,240
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot M915601 & M915602
- Oct 2021
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · METFORMIN HYDROCHLORIDE
- ModerateMetformin Hydrochloride Extended-Release Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- HighMetformin Hydrochloride Extended-Release Tablets Recalled for Foreign Tablet Contamination
FDA (Drugs) · 2025-04-02
- SevereMetformin Hydrochloride Extended-Release Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2022-02-02
- ModerateSun Pharmaceutical Recalls Metformin Hydrochloride Tablets Due to Foreign Substance
FDA (Drugs) · 2021-05-19
- LowSun Pharmaceutical Recalls Metformin Hydrochloride Extended-Release Tablets
FDA (Drugs) · 2021-04-14
Same manufacturer · VIONA PHARMACEUTICALS INC
See all →- ModerateTavaborole topical solution recalled from three lots because of discoloration
FDA (Drugs) · 2025-10-22
- ModerateTavaborole topical solution recalled after discoloration found in one lot
FDA (Drugs) · 2025-08-27
- HighDapsone Topical Gel Recalled Due to Crystallization Defect
FDA (Drugs) · 2025-01-08
- ModerateDapsone Gel Recalled Nationwide for Crystallization
FDA (Drugs) · 2025-01-08
- ModerateDapsone Gel 7.5% recalled nationwide due to crystallization
FDA (Drugs) · 2024-11-13
Same hazard · ndma contamination
See all →- ModerateMetformin 750 mg Extended Release Recalled for NDMA Contamination
FDA (Drugs) · 2022-01-19
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-11-25
- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-07-08
- SevereAmneal Recalls Nizatidine Oral Solution Due to Potential NDMA Contamination
FDA (Drugs) · 2020-05-06
- SeverePerrigo Recalls Ranitidine Tablets Due to Possible N-Nitrosodimethylamine Contamination
FDA (Drugs) · 2020-03-25